Drug repositioning for Alzheimer's disease

Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B. Dunnett; Paul Edison; Jim J. Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard

doi:10.1038/nrd3869

Drug repositioning for Alzheimer's disease

Anne Corbett, James Pickett, Alistair Burns, Jonathan Corcoran, Stephen B. Dunnett, Paul Edison, Jim J. Hagan, Clive Holmes, Emma Jones, Cornelius Katona, Ian Kearns, Patrick Kehoe, Amrit Mudher, Anthony Passmore, Nicola Shepherd, Frank Walsh, Clive Ballard

Research output: Contribution to journal › Article › peer-review

231 Citations (Scopus)

Abstract

Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.

Original language	English
Pages (from-to)	833-846
Number of pages	14
Journal	Nature Reviews Drug Discovery
Volume	11
Issue number	11
DOIs	https://doi.org/10.1038/nrd3869
Publication status	Published - Nov 2012

Keywords

Alzheimer Disease
Animals
Clinical Trials as Topic
Drug Approval
Drug Design
Drug Evaluation, Preclinical
Drug Industry
Humans

Access to Document

10.1038/nrd3869

Cite this

@article{150b49124b0e4db0a6e040d95a86f4e2,

title = "Drug repositioning for Alzheimer's disease",

abstract = "Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.",

keywords = "Alzheimer Disease, Animals, Clinical Trials as Topic, Drug Approval, Drug Design, Drug Evaluation, Preclinical, Drug Industry, Humans",

author = "Anne Corbett and James Pickett and Alistair Burns and Jonathan Corcoran and Dunnett, {Stephen B.} and Paul Edison and Hagan, {Jim J.} and Clive Holmes and Emma Jones and Cornelius Katona and Ian Kearns and Patrick Kehoe and Amrit Mudher and Anthony Passmore and Nicola Shepherd and Frank Walsh and Clive Ballard",

year = "2012",

month = nov,

doi = "10.1038/nrd3869",

language = "English",

volume = "11",

pages = "833--846",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Drug repositioning for Alzheimer's disease

AU - Corbett, Anne

AU - Pickett, James

AU - Burns, Alistair

AU - Corcoran, Jonathan

AU - Dunnett, Stephen B.

AU - Edison, Paul

AU - Hagan, Jim J.

AU - Holmes, Clive

AU - Jones, Emma

AU - Katona, Cornelius

AU - Kearns, Ian

AU - Kehoe, Patrick

AU - Mudher, Amrit

AU - Passmore, Anthony

AU - Shepherd, Nicola

AU - Walsh, Frank

AU - Ballard, Clive

PY - 2012/11

Y1 - 2012/11

N2 - Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.

AB - Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.

KW - Alzheimer Disease

KW - Animals

KW - Clinical Trials as Topic

KW - Drug Approval

KW - Drug Design

KW - Drug Evaluation, Preclinical

KW - Drug Industry

KW - Humans

U2 - 10.1038/nrd3869

DO - 10.1038/nrd3869

M3 - Article

C2 - 23123941

SN - 1474-1776

VL - 11

SP - 833

EP - 846

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 11

ER -

Drug repositioning for Alzheimer's disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this